Positive News SentimentPositive NewsNASDAQ:LPTX Leap Therapeutics (LPTX) Stock Price, News & Analysis $2.20 +0.03 (+1.38%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.16▼$2.2250-Day Range$1.69▼$2.6352-Week Range$1.24▼$5.00Volume75,739 shsAverage Volume247,478 shsMarket Capitalization$56.32 millionP/E RatioN/ADividend YieldN/APrice Target$10.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Leap Therapeutics alerts: Email Address Leap Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside372.7% Upside$10.40 Price TargetShort InterestBearish3.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.66) to ($1.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.69 out of 5 starsMedical Sector481st out of 936 stocksPharmaceutical Preparations Industry221st out of 436 stocks 3.5 Analyst's Opinion Consensus RatingLeap Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLeap Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Leap Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.80% of the float of Leap Therapeutics has been sold short.Short Interest Ratio / Days to CoverLeap Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Leap Therapeutics has recently increased by 6.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLeap Therapeutics does not currently pay a dividend.Dividend GrowthLeap Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LPTX. Previous Next 3.8 News and Social Media Coverage News SentimentLeap Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Leap Therapeutics this week, compared to 0 articles on an average week.Search Interest2 people have searched for LPTX on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Leap Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.30% of the stock of Leap Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.46% of the stock of Leap Therapeutics is held by institutions.Read more about Leap Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Leap Therapeutics are expected to grow in the coming year, from ($1.66) to ($1.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Leap Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Leap Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLeap Therapeutics has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Leap Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About Leap Therapeutics Stock (NASDAQ:LPTX)Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Read More LPTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LPTX Stock News HeadlinesMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Leap Therapeutics Amid Promising Clinical Trials and Strategic ExpansionMay 13, 2024 | investorplace.comLPTX Stock Earnings: Leap Therapeutics Beats EPS for Q1 2024July 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.May 13, 2024 | finanznachrichten.deLeap Therapeutics, Inc.: Leap Therapeutics Reports First Quarter 2024 Financial ResultsMay 13, 2024 | prnewswire.comLeap Therapeutics Reports First Quarter 2024 Financial ResultsApril 11, 2024 | markets.businessinsider.comLeap Therapeutics To Sell $40 Mln Of Shares In Private Placement; Stock Up Over 14%April 11, 2024 | prnewswire.comLeap Therapeutics Announces $40 Million Private PlacementMarch 26, 2024 | insidermonkey.com5 Best Biotech Penny Stocks to Invest InJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.March 19, 2024 | markets.businessinsider.comLeap Therapeutics: Promising Clinical Outcomes and Upcoming Catalysts Bolster Buy RatingMarch 18, 2024 | investorplace.comLPTX Stock Earnings: Leap Therapeutics Beats EPS for Q4 2023March 18, 2024 | finanznachrichten.deLeap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 18, 2024 | finance.yahoo.comLeap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 15, 2024 | finance.yahoo.comLPTX Apr 2024 5.000 callFebruary 17, 2024 | finance.yahoo.comLPTX Mar 2024 7.000 callJanuary 26, 2024 | markets.businessinsider.comOutperform Rating on Leap Therapeutics Amid Promising Gastric Cancer Trial OutcomesJanuary 17, 2024 | msn.comEvolus, Leap Therapeutics among healthcare moversJanuary 16, 2024 | finance.yahoo.comLeap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers SymposiumSee More Headlines Receive LPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LPTX CUSIPN/A CIK1509745 Webwww.leaptx.com Phone(617) 714-0360FaxN/AEmployees54Year FoundedN/APrice Target and Rating Average Stock Price Target$10.40 High Stock Price Target$17.50 Low Stock Price Target$5.50 Potential Upside/Downside+368.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.00% Return on Assets-68.93% Debt Debt-to-Equity RatioN/A Current Ratio5.38 Quick Ratio5.38 Sales & Book Value Annual Sales$1.50 million Price / Sales37.89 Cash FlowN/A Price / Cash FlowN/A Book Value$2.35 per share Price / Book0.94Miscellaneous Outstanding Shares25,600,000Free Float22,707,000Market Cap$56.83 million OptionableOptionable Beta0.32 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Douglas E. Onsi J.D. (Age 55)CFO, General Counsel, Treasurer & Secretary, President, CEO & Director Comp: $1.1MMr. Augustine J. Lawlor (Age 67)Chief Operating Officer Comp: $749.81kDr. Cynthia A. Sirard M.D. (Age 54)Chief Medical Officer Comp: $747.57kDr. Jason S. Baum Ph.D. (Age 45)Chief Scientific Officer Mr. Mark O'Mahony (Age 53)Chief Manufacturing Officer Ms. Christine M. Granfield (Age 56)VP and Head of Regulatory Affairs & Quality More ExecutivesKey CompetitorsProPhase LabsNASDAQ:PRPHDesign TherapeuticsNASDAQ:DSGN23andMeNASDAQ:MEShattuck LabsNASDAQ:STTKAbeona TherapeuticsNASDAQ:ABEOView All CompetitorsInstitutional OwnershipKey Client Fiduciary Advisors LLCBought 51,838 shares on 7/16/2024Ownership: 1.113%Vanguard Group Inc.Bought 457,904 shares on 5/10/2024Ownership: 3.389%Acadian Asset Management LLCBought 219,563 shares on 5/10/2024Ownership: 1.103%View All Institutional Transactions LPTX Stock Analysis - Frequently Asked Questions How have LPTX shares performed this year? Leap Therapeutics' stock was trading at $4.15 at the beginning of 2024. Since then, LPTX shares have decreased by 47.0% and is now trading at $2.20. View the best growth stocks for 2024 here. How were Leap Therapeutics' earnings last quarter? Leap Therapeutics, Inc. (NASDAQ:LPTX) posted its quarterly earnings results on Monday, May, 13th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.06. When did Leap Therapeutics' stock split? Shares of Leap Therapeutics reverse split on Wednesday, June 21st 2023. The 1-10 reverse split was announced on Wednesday, June 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Leap Therapeutics' major shareholders? Top institutional investors of Leap Therapeutics include Key Client Fiduciary Advisors LLC (1.11%). View institutional ownership trends. How do I buy shares of Leap Therapeutics? Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Leap Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Leap Therapeutics investors own include Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Amarin (AMRN), OPKO Health (OPK) and VYNE Therapeutics (VYNE). This page (NASDAQ:LPTX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.